Skip to main content
Assets
Pfizer logo
PFE.NYSE
Pfizer
Health Care · Pharmaceuticals

Global pharmaceutical company developing vaccines and medicines for oncology, inflammation, cardiovascular, and rare diseases including COVID-19 vaccine.

HQ: United StatesListed: United States

Profile & Fundamentals

Pfizer: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.

Profile & Fundamentals

Pfizer Profile & Fundamentals

Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.

Interactive annual & quarterly chartsAI financial reviewsReported source tables
Explore this pageJump to a Profile & Fundamentals section

Company and Market Context

Company Profile & Ownership

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

PFE.NYSE

Company profile record

Pfizer Inc

Common Stock · Health Care · Pharmaceuticals

Official website

Company

Company / asset
Pfizer Inc
Security type
Common Stock
Sector
Health Care
Industry
Pharmaceuticals
HQ
🇺🇸 United States
Head office
66 Hudson Boulevard East, New York, NY, United States, 10001-2192

Leadership & scale

Chief executive
Dr. Albert Bourla D.V.M., Ph.D.
CEO year born
1962
Full-time employees
75K
Fiscal year end
December
IPO date
1942-06-22

Fundamentals snapshot

Updated 2026-09-13
Market Cap
USD 157.6B
P/E
36.4x
Revenue (Q2 26)
USD 15.0B
Profit (Q2 26)
USD -246.0M
Dividend Yield
4.4%
Revenue (FY 25)
USD 62.6B
Shares in public float
5.7B
Insider ownership
0.1%

Reporting & identifiers

Symbol
PFE.NYSE
Listing
🇺🇸 United States | Dividend Tax: 30%
Ticker Currency
USD
Income Statement Currency
USD
Balance Sheet Currency
USD
Cash Flow Currency
USD
EPS Currency
USD
Contract Type
SPOT
ISIN
US7170811035
Asset ID
equity_6450e9e7-4c57-5c72-97d1-057751df8e53

Ownership

Shares Outstanding

Shares OutstandingAnnual reported shares outstanding. Values in shares.5.51B5.68B5.85B6.02B6.19BJan 2017Apr 2019Jul 2021Oct 2023Jan 2026
  • Shares outstanding
Annual reported shares outstanding. Values in shares.

Top holders

  1. BlackRock Inc498,257,550 shares · 8.74% · Reported 2026-03-31
  2. Vanguard Capital Management, LLC369,430,012 shares · 6.48% · Reported 2026-03-31
  3. State Street Corp301,589,865 shares · 5.29% · Reported 2026-03-31
  4. Vanguard MStar Total Stk Mkt Idx Invest181,491,199 shares · 3.18% · Reported 2026-07-31
  5. Vanguard 500 Index Investor149,626,158 shares · 2.63% · Reported 2026-07-31
  6. Geode Capital Management, LLC133,561,742 shares · 2.34% · Reported 2026-03-31
  7. Vanguard Portfolio Management, LLC116,734,695 shares · 2.05% · Reported 2026-03-31
View more holders (8)
  1. Fisher Asset Management, LLC109,067,291 shares · 1.91% · Reported 2026-06-30
  2. Morgan Stanley - Brokerage Accounts92,685,370 shares · 1.63% · Reported 2026-03-31
  3. iShares Core S&P 500 ETF75,864,389 shares · 1.33% · Reported 2026-08-31
  4. Fidelity 500 Index73,699,750 shares · 1.29% · Reported 2026-07-31
  5. State Street® SPDR® S&P 500® ETF69,817,535 shares · 1.23% · Reported 2026-08-31
  6. Northern Trust Corp62,026,552 shares · 1.09% · Reported 2026-03-31
  7. NORGES BANK61,505,586 shares · 1.08% · Reported 2026-06-30
  8. Massachusetts Financial Services Company56,911,830 shares · 1.00% · Reported 2026-03-31

Earnings, Profitability & Valuation

Earnings & Revenue

Revenue, Net Income, and Free Cash Flow

Revenue, Net Income, and Free Cash FlowAnnual reported financial results, converted using the statement's recorded USD conversion. Missing values are omitted. Values in USD.-7.69B21.77B51.23B80.69B110.15BDec 2016Apr 2019Jul 2021Oct 2023Dec 2025
  • Revenue
  • Free cash flow
  • Net income
Annual reported financial results, converted using the statement's recorded USD conversion. Missing values are omitted. Values in USD.

Valuation

Historical P/E Ratio

Historical P/E RatioPublished valuation snapshots. Trailing four-quarter earnings where available; annual earnings otherwise. Non-positive earnings are omitted. Values in times earnings.2.6922.7642.8262.8882.94Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
  • Published P/E
Published valuation snapshots. Trailing four-quarter earnings where available; annual earnings otherwise. Non-positive earnings are omitted. Values in times earnings.

Profitability & Margins

Profitability Margins

Profitability MarginsAnnual gross, operating, net income and free cash flow divided by revenue for matching reporting dates. Values in percent.-3.2317.2137.6658.1178.55Dec 2016Apr 2019Jul 2021Oct 2023Dec 2025
  • Gross margin
  • Operating margin
  • Net margin
  • Free cash flow margin
Annual gross, operating, net income and free cash flow divided by revenue for matching reporting dates. Values in percent.

Complete Research Workspace

Unlock the complete Profile & Fundamentals

Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.